M-M-R®II vaccine efficacy-- robust coverage starting after the first dose

M-M-R®II vaccine efficacy—robust coverage starting after the first dose1

Help protect against measles, mumps, and rubella with high immune response rates

In a clinical trial of 284a patients, M-M-R®II seroconversion rates were high after the first dose.

aClinical studies of 284 triple-seronegative children 11 months to 7 years of age demonstrated that M-M-R®II is highly immunogenic and generally well-tolerated. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible persons. However, a small percentage (1%–5%) of vaccinees may fail to seroconvert after the primary dose.

M-M-R®II immunization provides coverage that can last over 10 years

Based on data from a clinical study, neutralizing and ELISA antibodies to MMR viruses were still found years after primary vaccination.

Antibodies were detected 11–13 years after primary vaccination in:

95%–100%
of individuals
against measles
74%–91%
of individuals
against mumps
90%–100%
of individuals
against rubella

Learn More About Stocking M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) in Your Professional Practice

Actual size not shown

Looking to stock M-M-R®II vaccine in your practice?

Simply register or log in to your account to get started.


Dosage and Administration for M-M-R®II (Measles, Mumps, & Rubella Virus Vaccine Live)

Dosage and Administration

Discover the dosing regimen and administration of M-M-R®II.

CDC ACIP Recommendations for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

CDC’s ACIP Recommendations

Find out about the ACIP recommendations for MMR vaccinations in pediatric patients.2

ref2

Reference

  1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2022. Updated February 17, 2022. Accessed March 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
ref1

Reference

  1. Marin M, Broder KR, Temte JL, et al. Centers for Disease Control and Prevention. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(3):1-12.

Indications and Usage for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

M-M-R®II is contraindicated in certain individuals, including those with: a history of

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-MMR-00141 05/22